CatalystFDA/Bio

Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results

Cue Biopharma shares jump 41.6% premarket on Phase 2 trial results.

What changed

Cue Biopharma shares jump 41.6% premarket on Phase 2 trial results.

Why it matters

Cue Biopharma shares jump 41.6% premarket on Phase 2 trial results. — impact context not separately stored; see What changed.

Sources